Estrogen and Progesterone Receptors in Endometrial Cancer: Where Are We Today?
Received Date: Feb 13, 2018 / Accepted Date: Feb 15, 2018 / Published Date: Feb 22, 2018
Immunohistochemistry of estrogen receptor (ER) and progesterone receptor (PR) is not routinely adopted by clinicians for the management of endometrial cancers. However, they may have significant importance in determining tumor behaviour and selection of an appropriate treatment protocol. An insight into the role of ER and PR in endometrial cancers is needed for optimizing outcome. The mechanism of action of these receptors in endometrial carcinoma needs to be clearly understood.
Structure and Function
ER and PR are ligand dependent transcription factors belonging to the nuclear receptor superfamily. Their binding to different DNA sites initiates the expression of specific genes. There are two classes of ERs:
1. Nuclear ER (ERα and ERβ) are members of nuclear receptor family. They are expressed distinctly in various tissues  particularly the endometrium leading to cellular proliferation and differentiation . ER-α binds to estrogens with high affinity and low capacity and vice versa with ER-β. ER- β is needed for organization and adhesion of epithelial cells and hence for functional maturation of differentiated tissues [3,4].
2. Membrane estrogen receptors (mERs)-G protein coupled estrogen receptor (GPER)
Progesterone receptor (PR) also has 2 isoforms which are functionally distinct transcription factors:
1. PR-A-Has estrogen antagonistic action and modulates the antiproliferative effects of progesterone in uterus
2. PR-B-Has estrogen agonist action and induces cell growth in absence of PR-A .
ER and PR in Endometrial Cancers
Endometrial cancer is hormone dependent. ER-α, PR-A and PR-B have been quantitatively associated with the tumour’s histological differentiation [9,10], response to therapy  and metastatic potential . Loss of these receptors occurs early in endometrial carcinogenesis. Endometrial carcinoma has lower level of these receptors in comparison with normal endometrium or endometrial hyperplasia .
In endometrial cancer, ER-α expression decreases in both endometrial glands and stroma [14,15]. As the grade of tumor advances, there is further reduction in stromal expression16. Reduced or absent PR-A or PR-B expression is observed in endometrial cancers 16. Similar pattern of expression of PR-A and ER-α is found in endometrial glands and stroma cells. The imbalance in PR-A to PR-B ratio is frequently associated with the development of endometrial cancer [16-18,19]. The relative over-expression of PR-B, which is referred to as an endometrial estrogen agonist , without transcriptional repression by PR-A, may be related to the metastatic potential and partially cause deviation from sex steroidal dependency in endometrial cancers . PR-A/PR-B, if <1, has a shorter diseasefree and overall survival . Therefore, the expression of PR-B is more sinister. Whether this ratio could be used as a prognostic tool to determine progesterone responsiveness is still unclear. Conflicting evidences exist regarding the PR status in endometrial malignancies. PR-B predominance  or loss of both PR isoforms may be seen in advanced endometrial malignancies . Poorly differentiated endometrial cancer cells may only express PR-A .
Impact on Clinical Decision Making
Five-year survival rate (stage I) and median survival time (stages IIIV, recurrences) for patients with PR positive endometrial cancers were significantly better as compared to PR negative cancers. ER does not have significant prognostic relevance .
Reduced expression of ER-α and PR-A in stromal cells of endometrium indicates invasiveness . Loss of hormone receptors in endometrial biopsies prior to surgical staging independently predicts lymph node metastasis. Simultaneous ER and PR negativity significantly adds predictive and prognostic information for low risk grade 1 or 2 endometrioid adenocarcinomas, both in need for lymphadenectomy and adjuvant therapy .
There exists a significant correlation between PR-positive tumors and grade, surgical stage, histology, adnexal spread, disease free survival and recurrence . Thus, PR/ER immunohistochemistry appears to be a reliable means for predicting survival in endometrioid adenocarcinoma of endometrium, independent of other clinicopathological parameters .
Another challenge is the management of endometrial pre-cancers and cancers in the young women. The definitive treatment of endometrial cancers is surgical staging and hysterectomy. The need is to preserve fertility in these women. Progestrone therapy is utilized for fertility sparing in women with atypical endometrial hyperplasia or early stage well differentiated endometrioid adenocarcinomas as per guidelines. If response to therapy is achieved, definitive treatment is delayed till after conception. The overall response rate to progeseterone therapy is 50-70% . ER and PR positive tumors respond well to hormonal therapy. Only some PR negative tumors show good clinical response. ER and PR testing on endometrial biopsy specimen may be useful to determine response to progesterone therapy. However, this needs further research.
In early or recurrent endometrial cancers, the utilization of ER/PR testing on tumor tissue is not yet routinely practised. Prior to initiation of definitive treatment, ER and PR on immunohistochemistry of endometrial biopsy specimen may be useful in predicting lymph node, adnexal involvement and myometrial invasion. These parameters are critical determinants of extent of surgery.
Some questions remain and yet need to be addressed. Can we rely on ER/PR testing for determining response to progesterone therapy? Can we predict the biologic nature of endometrial cancer? Can higher grade more aggressive endometrial cancers be treated with lesser cytotoxic hormonal agents?
We may not have the answers yet. The approach can be to perform ER/PR immunohistochemistry testing, collect data, formulate studies and trials and follow up endometrial cancer patients for the answers. Treatment algorithms may need reprisal in the near future based on use of ER/PR testing.
- Mueller SO, Korach KS (2001) Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr Opin Pharmacol 1: 613-619.
- Yang P, Kriatchko A, Roy SK (2002) Expression of ER-alpha and ER-beta in the hamster ovary: differential regulation by gonadotropins and ovarian steroid hormones. Endocrinology 143: 2385-2398.
- Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, et al. (1997) Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
- Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.
- Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM (2000) Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289: 1751-1754.
- Singh M, Zaino RJ, Filiaci VJ, Leslie KK (2007) Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 106: 325-333.
- Savouret JF, Rauch M, Redeuilh G, Sar S, Chauchereau A, et al. (1994) Interplay between estrogens, progestins, retinoic acid and AP-1. J Biol Chem 269: 28955-28962.
- Lesniewicz T, Kanczuga-Koda L, Baltaziak M, Jarzabek K, Rutkowski R, et al. (2009) Comparative evaluation of estrogen and progesterone receptor expression with connexins 26 and 43 in endometrial cancer. Int J Gynecol Cancer 19: 1253-1257.
- Kerner H, Sabo E, Friedman M, Beck D, Samare O, et al. (1995) An immunohistochemical study of estrogen and progesterone receptors in adenocarcinoma of the endometrium and in the adjacent mucosa. Int J Gynecol Cancer 5: 275-281.
- Markman M (2005) Hormonal therapy of endometrial cancer. Eur J Cancer 41: 673-675.
- Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, et al. (2000) Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 6: 3937-3943.
- Fujimoto J, Sakaguchi H, Aoki I, Tamaya T (2000) Steroid receptors and metastatic potential in endometrial cancers. Eur J Cancer 4: S33.
- Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S (1996) Stepwise Abnormality of Sex Steroid Hormone Receptors, Tumor Suppressor Gene Products (p53 and Rb), and Cyclin E in Uterine Endometrioid Carcinoma. Cancer 77: 321-329.
- Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, et al. (2001) Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20: 6965-6969.
- Smuc T, Rizner TL (2009) Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol 301: 74-82.
- Gul AE, Keser SH, Barisik NO, Kandemir NO, Cakir C, et al. (2010) The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas. Diagn Pathol 5: 13.
- Arnett-Mansfield RL, de Fazio A, Wain GV, Jaworski RC, Byth K, et al. (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61: 4576-4582.
- Vegeto E, Shahbaz MM (1993) Human progesterone receptor A form is a cell and promoter specific repressor of human progesterone receptor B function. Mol Endocrinol 7: 1244-1255.
- Khan JA, Amazit L, Bellance C, Guiochon-Mantel A, Lombès M, et al. (2011) p38 and p42/44 MAPKs differentially regulate progesterone receptor A and B isoform stabilization. Mol Endocrinol 25: 1710-1724
- Ryan AJ, Susil B, Jobling TW, Oehler MK (2005) Endometrial cancer. Cell Tissue Res 322: 53-61.
- Jongen V, Briët J, de Jong R (2009) Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol 112: 537-542.
- Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T (1995) Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 16: 254-260.
- Kumar NS, Richer J, Owen G, Litman E, Horwitz KB, et al. (1998) Selective Down-Regulation of Progesterone Receptor Isoform B in Poorly Differentiated Human Endometrial Cancer Cells: Implications for Unopposed Estrogen Action. Cancer Res 58: 1860-1865.
- Kleine W, Maier T, Geyer H, Pfleiderer A (1990) Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38: 59-65.
- Kreizman-Shefer H, Pricop J, Goldman S, Elmalah I, Shalev E (2014) Distribution of estrogen and progesterone receptors isoforms in endometrial cancer. Diagnostic Pathology 9: 77.
- Trovik J, Wik E, Werner HMJ, Krakstad C, Harald H, et al. (2013) Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. European Journal of Cancer 49: 3431-3441.
- Zafran N, Levin A, Goldman S, Shalev E (2009) Progesterone receptor’s profile and the effect of the hormone and its derivatives on invasiveness and MMP2 secretion in endometrial carcinoma cell lines. Harefuah 148: 416-419.
- Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79: 320-327.
Citation: Swasti (2018) Estrogen and Progesterone Receptors in Endometrial Cancer: Where Are We Today?. Gynecol Obstet 8: e127. DOI: 10.4172/2161-0932.1000e127
Copyright: ©2018 Swasti. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
- Total views: 1055
- [From(publication date): 0-2018 - Feb 18, 2019]
- Breakdown by view type
- HTML page views: 995
- PDF downloads: 60